The source records describe two separate proposed securities class actions announced Aug. 21, 2026. AEVEX Corp. investors who bought shares in or traceable to the company’s April 2026 IPO or between April 17 and June 4, 2026, have until Oct. 20, 2026, to seek lead plaintiff appointment in Rosenberg v. AEVEX Corp. The complaint alleges AEVEX concealed a pre-arranged plan to waive Madison Dearborn Partners’ 180-day lock-up and permit an eight-million-share secondary offering; the stock fell approximately 16% after the June 1 announcement and a further 7% after related disclosures. Separately, Aardvark Therapeutics investors who bought stock issued in or traceable to its Feb. 13, 2025, IPO or securities between Feb. 13, 2025, and May 14, 2026, must move for lead plaintiff appointment by Oct. 13, 2026. That lawsuit alleges investors were misled about ARD-101’s safety and clinical, regulatory and commercial prospects. No class has been certified in the Aardvark action.